Analyst Ratings For Adamas Pharmaceuticals (NASDAQ:ADMS) (NASDAQ:ADMS)
Today, Bank of America initiated coverage on Adamas Pharmaceuticals (NASDAQ:ADMS) (NASDAQ:ADMS) with a Buy with a price target of $39.00.
Some recent analyst ratings include
- 3/27/2018-Bank of America initiated coverage with a Buy rating.
- 2/23/2018-Noble Financial Reiterated Rating of Buy.
- 2/21/2018-William Blair Reiterated Rating of Outperform.
- 1/23/2018-Mizuho Reiterated Rating of Buy.
Recent Insider Trading Activity For Adamas Pharmaceuticals (NASDAQ:ADMS) (NASDAQ:ADMS)
Adamas Pharmaceuticals (NASDAQ:ADMS) (NASDAQ:ADMS) has insider ownership of 29.00% and institutional ownership of 77.25%.
- On 3/21/2018 Christopher B Prentiss, CAO, sold 567 with an average share price of $25.98 per share and the total transaction amounting to $14,730.66.
- On 3/21/2018 Gregory T Went, CEO, sold 4,541 with an average share price of $25.75 per share and the total transaction amounting to $116,930.75.
- On 3/21/2018 Rajiv Patni, Insider, sold 1,252 with an average share price of $25.94 per share and the total transaction amounting to $32,476.88.
- On 12/21/2017 Jennifer J. Rhodes, Insider, sold 440 with an average share price of $32.30 per share and the total transaction amounting to $14,212.00.
- On 6/21/2017 Great Point Partners Llc, Major Shareholder, sold 380,000 with an average share price of $17.08 per share and the total transaction amounting to $6,490,400.00.
- On 6/21/2017 Jennifer J. Rhodes, Insider, sold 1,041 with an average share price of $17.53 per share and the total transaction amounting to $18,248.73.
- On 6/19/2017 Great Point Partners Llc, Major Shareholder, sold 350,000 with an average share price of $17.05 per share and the total transaction amounting to $5,967,500.00.
Recent Trading Activity for Adamas Pharmaceuticals (NASDAQ:ADMS) (NASDAQ:ADMS)
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) closed the previous trading session at 25.70 up +1.30 5.32% with 253056 shares trading hands.
